Trending...
- Omnitronics launches Ecosystem Health Dashboard to enable proactive monitoring across dispatch environments
- New Research Identifies "The Great Junk Transfer": 49% of Americans Would Rather Inherit Nothing Than Sort Through a Relative's Belongings
- UK Financial Ltd Verifies Maya Preferred PRA Circulating Supply, Proving Its Eight-Year Promise of Under 1M Tokens After Chainlink Labs Agreement
Download
Photo courtesy of Labcorp
BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp® (NYSE: LH), a leading global life sciences company, today announced a new collaboration with HealthVerity, Inc., the leader in Identity, Privacy, Governance, and Exchange (IPGE) for real-world data (RWD), that will expand Labcorp's comprehensive, end-to-end drug development and clinical trial programs.
More on ncarol.com
HealthVerity's IPGE platform, an integrated technology and RWD infrastructure, enables Labcorp Drug Development and other participating companies to access fully interoperable, HIPAA-compliant data from the U.S.'s largest ecosystem1 of health care and consumer data.
"This collaboration allows Labcorp to expand existing end-to-end solutions for drug and diagnostics development, commercialization and clinical trial efforts to include large-scale access to real-world data for research applications," said Dr. Paul Kirchgraber, CEO of Labcorp Drug Development. "By applying advanced analytics, Labcorp can help its clients improve their processes and reach better outcomes. Our substantial repository of test results can also help study sponsors more quickly and accurately assess patient eligibility for clinical trials, enroll patients faster and accelerate the availability of new medicines."
Now more than ever, study sponsors are seeing the potential of RWD to yield longitudinal patient insights before, during and after trials. With more predictive analytics and artificial intelligence applications requiring comprehensive and fully interoperable RWD, Labcorp can align de-identified patient data with ten times greater accuracy2 than industry alternatives by using the HealthVerity IPGE platform. In addition, access to HealthVerity's RWD with on-demand de-identification and data linkage capabilities reinforces Labcorp's ability to be a trusted source of information for its clients.
"Fragmentation of patient data is at an all-time high, and the goal is no longer just connecting this data," said Andrew Kress, CEO of HealthVerity. "Rather, the goal is making data more accessible and useful for gaining a detailed understanding of patient journeys. With analytics and applications requiring more frictionless access to the data itself, the HealthVerity IPGE platform stands alone in offering the ability to combine transaction-level patient data in a de-identified, fully interoperable manner, and delivering it directly into the client's applications of choice."
Labcorp is an investor in HealthVerity through the Labcorp Venture Fund.
About Labcorp
Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. With over 75,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of $16 billion in FY2021. Learn more about us at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp.
More on ncarol.com
About HealthVerity
Pharmaceutical manufacturers, payers, and government organizations have partnered with HealthVerity to solve some of their most complicated use cases through transformative technologies and real-world data infrastructure. The HealthVerity IPGE platform, based on the foundational elements of Identity, Privacy, Governance, and Exchange, enables the discovery of real-world data across the broadest healthcare data ecosystem, the building of more complete and accurate patient journeys and the ability to power best-in-class analytics and applications with flexibility and ease. Together with our partners, HealthVerity has built the modern way to data for the health insights economy. To learn more about the HealthVerity IPGE platform, visit www.healthverity.com
1 Internal data from HealthVerity
2 Internal data from HealthVerity
Contacts
Labcorp Contacts:
Media: Christopher Allman-Bradshaw — 336-436-8263
Media@Labcorp.com
Investors: Chas Cook — 336-436-5076
Investor@Labcorp.com
HealthVerity Media Contact:
Jennifer Kaczmarczyk
Vice President, Marketing
jkaczmarczyk@healthverity.com
0) { // Create container for hi-res image jQuery('#bw-release-hires').append('
'); }; }); ]]>
Contacts
Labcorp Contacts:
Media: Christopher Allman-Bradshaw — 336-436-8263
Media@Labcorp.com
Investors: Chas Cook — 336-436-5076
Investor@Labcorp.com
HealthVerity Media Contact:
Jennifer Kaczmarczyk
Vice President, Marketing
jkaczmarczyk@healthverity.com
Photo courtesy of Labcorp
BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp® (NYSE: LH), a leading global life sciences company, today announced a new collaboration with HealthVerity, Inc., the leader in Identity, Privacy, Governance, and Exchange (IPGE) for real-world data (RWD), that will expand Labcorp's comprehensive, end-to-end drug development and clinical trial programs.
More on ncarol.com
- RPR Promotes Emily Line to Chief Strategy Officer and Janine Sieja to Chief Product Officer
- Expanding Beyond Space as New Drone Market Opportunities Accelerate Growth: Ascent Solar Technologies (N A S D A Q: ASTI)
- Lauren Merrell, Dale Sorensen Real Estate, announces price improvement for an extraordinary island retreat
- Portalz Publishes FES World First Architecture Introducing a New Cryptographic Platform
- Cellofest Brings Free Cello Concerts and Community Events to Bethany Beach August 5–16
HealthVerity's IPGE platform, an integrated technology and RWD infrastructure, enables Labcorp Drug Development and other participating companies to access fully interoperable, HIPAA-compliant data from the U.S.'s largest ecosystem1 of health care and consumer data.
"This collaboration allows Labcorp to expand existing end-to-end solutions for drug and diagnostics development, commercialization and clinical trial efforts to include large-scale access to real-world data for research applications," said Dr. Paul Kirchgraber, CEO of Labcorp Drug Development. "By applying advanced analytics, Labcorp can help its clients improve their processes and reach better outcomes. Our substantial repository of test results can also help study sponsors more quickly and accurately assess patient eligibility for clinical trials, enroll patients faster and accelerate the availability of new medicines."
Now more than ever, study sponsors are seeing the potential of RWD to yield longitudinal patient insights before, during and after trials. With more predictive analytics and artificial intelligence applications requiring comprehensive and fully interoperable RWD, Labcorp can align de-identified patient data with ten times greater accuracy2 than industry alternatives by using the HealthVerity IPGE platform. In addition, access to HealthVerity's RWD with on-demand de-identification and data linkage capabilities reinforces Labcorp's ability to be a trusted source of information for its clients.
"Fragmentation of patient data is at an all-time high, and the goal is no longer just connecting this data," said Andrew Kress, CEO of HealthVerity. "Rather, the goal is making data more accessible and useful for gaining a detailed understanding of patient journeys. With analytics and applications requiring more frictionless access to the data itself, the HealthVerity IPGE platform stands alone in offering the ability to combine transaction-level patient data in a de-identified, fully interoperable manner, and delivering it directly into the client's applications of choice."
Labcorp is an investor in HealthVerity through the Labcorp Venture Fund.
About Labcorp
Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. With over 75,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of $16 billion in FY2021. Learn more about us at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp.
More on ncarol.com
- Blue Sky Capital Strategies, LLC awarded Leasing and Financial Services agreement with Premier Inc
- Michael M. Thomas Expands Executive Leadership Across Central India Outreach and Royal Trinity School
- Northeast Airlines and Travel, Inc. Initiates FAA Part 121 Certification for Boeing 737-800 Freighter Cargo Operations
- Walker's Realty and North Jersey Properties Introduce Extraordinary Luxury Estate for Rent in West Orange, New Jersey
- Extreme Heat Strains Home Appliances: Appliance EMT Offers "Summer Rescue" Relief
About HealthVerity
Pharmaceutical manufacturers, payers, and government organizations have partnered with HealthVerity to solve some of their most complicated use cases through transformative technologies and real-world data infrastructure. The HealthVerity IPGE platform, based on the foundational elements of Identity, Privacy, Governance, and Exchange, enables the discovery of real-world data across the broadest healthcare data ecosystem, the building of more complete and accurate patient journeys and the ability to power best-in-class analytics and applications with flexibility and ease. Together with our partners, HealthVerity has built the modern way to data for the health insights economy. To learn more about the HealthVerity IPGE platform, visit www.healthverity.com
1 Internal data from HealthVerity
2 Internal data from HealthVerity
Contacts
Labcorp Contacts:
Media: Christopher Allman-Bradshaw — 336-436-8263
Media@Labcorp.com
Investors: Chas Cook — 336-436-5076
Investor@Labcorp.com
HealthVerity Media Contact:
Jennifer Kaczmarczyk
Vice President, Marketing
jkaczmarczyk@healthverity.com
0) { // Create container for hi-res image jQuery('#bw-release-hires').append('
'); }; }); ]]>
Contacts
Labcorp Contacts:
Media: Christopher Allman-Bradshaw — 336-436-8263
Media@Labcorp.com
Investors: Chas Cook — 336-436-5076
Investor@Labcorp.com
HealthVerity Media Contact:
Jennifer Kaczmarczyk
Vice President, Marketing
jkaczmarczyk@healthverity.com
Filed Under: Business
0 Comments
Latest on ncarol.com
- Ten-Time Combat-Deployed U.S. Army Major Imprisoned For Telling The Truth In North Carolina Court Rm
- ImagineX Acquires Payteros to Strengthen Digital Transformation Capabilities
- From Pizza to Playlists: Marty The Pizza Guy Delivers Three Delicious New Songs
- Adelaide's Army of Hope Celebrates 501(c)(3) Status Ahead of Swing Fore Hope Golf Tournament
- Salestrics Introduces PraiseEngine: The AI-Native Review Engine Built to Fix Social Proof
- NVM Pet Celebrates a Decade of Growth by Honoring the People Behind Its Success
- Mike "The Situation" Sorrentino Celebrates Opening of Second Archangel Centers Location
- Big Money Retirement Opens Dedicated Charlotte Office to Better Serve Growing Client Base
- K2 Integrity Names Michael Kallabat Global Head of Investigations and Disputes
- Socialhose Eyes Southeast Asia and Rejects the Copy-Paste Expansion Playbook
- $40 Billion Global Market Value by 2030 Projected in Unmanned Aerial Vehicle or Other Drone Technology Sector, Growing at 9.2% Compound Annual Growth
- Charlotte-based Steady Tax & Bookkeeping launches to support small businesses nationwide
- Recreation Ponds: The Next Big Backyard Pond Trend?
- $620 Million in Recent Government Contract Awards with More Than $1.2 Billion in Annualized Revenue: Circle8 Group (N A S D A Q: CIRC)
- Lewis County Hydrogen Alliance Launches Phase 1 Work to Turn Forest Residuals into Fuel-Grade Hydrogen and Dispatchable Clean Power
- Next Gen Fibre Selects netElastic vBNG and CGNAT to Fuel Rapid Nationwide Expansion and Eliminate Network Bottlenecks
- Boston Industrial Solutions, Inc. Introduces SAP-G70 Primer for bonding silicone to silicone and other materials
- 'Reflections: Enlightening Insights Into the Divine Mystery' — The Latest Book by Philosopher Steven Colborne
- Scott G. Hoy of Hoy Law Earns 11th Consecutive Super Lawyers Selection
- L2 Aviation Selected for U.S. Air Force KC-46 CASPER Multiple Award Contract